AVROBIO, Inc. (AVRO)
| Previous Close | 1.3900 |
| Open | 1.4000 |
| Bid | 1.3500 x 200 |
| Ask | 1.3900 x 200 |
| Day's Range | 1.3700 - 1.4000 |
| 52 Week Range | 0.8800 - 1.6500 |
| Volume | |
| Avg. Volume | 211,996 |
| Market Cap | 61.729M |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | 5.09 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
AVROBIO and Tectonic Therapeutic Announce Merger
CAMBRIDGE, Mass. & WATERTOWN, Mass., January 30, 2024--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction (the "Merger"). Under the terms of the agreement, AVR
- Business Wire
AVROBIO to Explore Strategic Alternatives
CAMBRIDGE, Mass., July 12, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.
- Business Wire
AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million
CAMBRIDGE, Mass., June 12, 2023--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis to Novartis for $87.5 million in cash.
